• Publications
  • Influence
Levodopa and the progression of Parkinson's disease.
BACKGROUND Despite the known benefit of levodopa in reducing the symptoms of Parkinson's disease, concern has been expressed that its use might hasten neurodegeneration. This study assessed theExpand
  • 1,452
  • 57
Variable expression of Parkinson's disease
The DATATOP database, which includes clinical information on 800 patients with early untreated Parkinson's disease (PD), is well suited to explore clinical heterogeneity in PD. Patients withExpand
  • 993
  • 40
  • PDF
Detection of Huntington’s disease decades before diagnosis: the Predict-HD study
Objective: The objective of the Predict-HD study is to use genetic, neurobiological and refined clinical markers to understand the early progression of Huntington’s disease (HD), prior to the pointExpand
  • 635
  • 37
  • PDF
A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study.
CONTEXT Monotherapy with rasagiline mesylate may be useful in early Parkinson disease (PD). OBJECTIVE To evaluate the safety and efficacy of the selective monoamine oxidase type B inhibitorExpand
  • 502
  • 33
  • PDF
A polymorphic DNA marker genetically linked to Huntington's disease
Family studies show that the Huntington's disease gene is linked to a polymorphic DNA marker that maps to human chromosome 4. The chromosomal localization of the Huntington's disease gene is theExpand
  • 2,086
  • 29
Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline.
BACKGROUND Parkinson disease (PD) is a degenerative neurological disorder for which no treatment has been shown to slow the progression. OBJECTIVE To determine whether a range of dosages ofExpand
  • 903
  • 29
  • PDF
Huntington disease
Over the past 5 years, considerable investigative attention has focused on Huntington disease, largely inspired by the neuropharmacologic advances made against Parkinson disease and the renewal ofExpand
  • 565
  • 29
Unified Huntington's disease rating scale: Reliability and consistency
The Unified Huntington's disease Rating Scale (UHDRS) was developed as a clinical rating scale to assess four domains of clinical performance and capacity in HD: motor function, cognitive function,Expand
  • 927
  • 27
Trinucleotide repeat length instability and age of onset in Huntington's disease
The initial observation of an expanded and unstable trinucleotide repeat in the Huntington's disease gene has now been confirmed and extended in 150 independent Huntington's disease families. HDExpand
  • 972
  • 23
Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset.
Huntington's disease (HD) is an autosomal dominant neurodegenerative disease caused by a triplet (CAG) expansion mutation. The length of the triplet repeat is the most important factor in determiningExpand
  • 635
  • 23